India's AI-enabled clinical trials market is projected to grow from USD 140 million in the current year to USD 803 million by 2035, implying an approximately 21.4% compound annual growth rate (CAGR), according to a report added to ResearchAndMarkets.com's offering. Growth is being supported by rising trial activity, pharmaceutical and biotechnology research investment, healthcare digitization, and wider use of decentralized and hybrid trials. Sponsors and contract research organizations (CROs) are applying artificial intelligence to trial design, eligibility screening, enrollment forecasting, electronic data capture, adverse-event triage and remote patient monitoring. The report identifies software and platforms as the largest component segment, while services such as data annotation, model validation, implementation and consulting are expected to grow fastest. Oncology leads adoption by therapeutic area, cloud-based deployment leads new implementations, pharmaceutical and biotechnology companies represent the largest end-user revenue share, and CROs are the fastest-growing adopters. South India and West India currently lead deployment, while North India is expected to expand rapidly. Adoption remains constrained by data privacy and cross-border transfer requirements, fragmented clinical records, uneven digital maturity, approval and systems-integration challenges, and a shortage of professionals combining clinical research and data-science expertise. The report assesses market size, forecasts, competitive positioning, technology maturity, regulation, partnerships, funding, licensing and market intensity through 2035.